Commonwealth Diagnostics International, Inc. (CDI) is pleased to announce its participation in the Blue Cross Blue Shield of Massachusetts Network. CDI is a diagnostic laboratory located in Salem, Massachusetts that offers a variety of products, services, and technologies that aid in the diagnosis of gastrointestinal disorders such as Small Intestinal Bacterial Overgrowth (SIBO) and Irritable Bowel Syndrome (IBS).
Gastrointestinal disorders affect millions of people every day, not only causing uncomfortable and painful symptoms like diarrhea, constipation, and abdominal pain but also impairing quality of life overall. Proper diagnosis and testing are essential to help provide the best treatment plans and help patients feel better fast. Healthcare providers and patients want access to affordable diagnostic options in the market that are easy to use and– most importantly– provide highly accurate results to ensure the best health outcomes. CDI’s proprietary testing model uses industry-leading clinical guidelines for breath testing pursuant to the North American Consensus for Breath Testing, the only standardized breath testing guidelines agreed to by 17 independent clinician-scientists from around the world.
All of CDI’s products can be ordered by a physician online and shipped to the patient’s home anywhere in the United States. The ease of ordering test kits and the ability for patients to administer tests in the comfort of their own home makes CDI unique, and that is why we understand the importance of partnering with insurance companies to provide patients access to our testing.
“CDI is committed to actively applying for participation with health plans across the country. We know that this partnership will help assist in the diagnosis of GI disorders for the 3 million BCBS members in Massachusetts. Our hope is to eventually broaden our partnership within the Blue Cross and Blue Shield network and other commercial insurance companies to allow more patients access to our testing.” says Lisa Richard, VP of Market Access from CDI.
The partnership with Blue Cross and Blue Shield of Massachusetts and future partnerships with other insurance providers will help lessen the burden of diagnostic testing for patients suffering from GI conditions. CDI is committed to ensuring that all patients have access to our tests and will continue to pursue in-network opportunities with insurance providers throughout the United States. For more information on CDI and our testing, please talk to your healthcare provider, visit our website at www.CommDx.com, or reach out directly via email to info@commdx.com.
